Make Informed Investment Decisions with Affordable Access to Experts
Exploring the current treatment landscape in the melanoma space, including IOVA's LN-144, with a specific focus on the checkpoint refractory populationTicker(s): IOVA
Name: Dr Sanjiv Agarwala - MD
Institution: St. Luke's Cancer Center | Temple University
- Chairman of Medical Oncology, Professor & Chief Hematology & Oncology St Luke’s Cancer Center & Temple University.
- Currently manages ~100 patients with melanoma.
- Internationally recognized investigator in the field of melanoma and immunotherapy; has led several clinical trials of immunotherapy and targeted therapy in melanoma.
Please describe your clinical practice; roughly how many patients with melanoma do you currently manage?
What is your current first line therapy in treating melanoma?Added By: c_admin
What are your thoughts on the potential for TIL therapies in this disease?Added By: c_admin
Can you please discuss the specific needs of the checkpoint refractory population.Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.